

**CLEOPATRA HOSPITAL COMPANY "S.A.E."
AND ITS SUBSIDIARIES**

**LIMITED REVIEW REPORT AND THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS PERIOD ENDED
30 JUNE 2022**

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Interim condensed consolidated financial statements For the six months period ended 30 June 2022

Index	Page
Limited review report	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of profit or loss	3
Interim condensed consolidated statement of comprehensive income	4
Interim condensed consolidated statement of changes in equity	5
Interim condensed consolidated statement of cash flows	6
Notes to the interim condensed consolidated financial statements	7 – 23



Limited Review Report on the Interim Financial Statements

To: The Board of Directors of Cleopatra Hospital Company (S.A.E.)

Introduction


We conducted our limited review on the accompanying interim condensed consolidated financial position of Cleopatra Hospital Company (S.A.E.) and its subsidiaries (the "Group") as at 30 June 2022 and the related interim condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six months period then ended. The management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting". Our responsibility is limited to express a conclusion on these interim condensed consolidated financial statements based on our limited review.

Scope of the limited review

We conducted our limited review in accordance with the Egyptian Standard on Limited Review Engagements (2410), "Limited Review of Interim Financial Statements Performed by the Auditor of the Entity". A limited review of the interim condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with the Egyptian Standards on Auditing and consequently does not enable us to obtain an assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed consolidated financial statements.

Conclusion

Based on our limited review, nothing has come to our attention which causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting".



Tamer Abdel Tawab
Member of Egyptian Society of Accountants & Auditors
Member of AICPA
R.A.A. 17996
F.R.A. 388

18 August 2022
Cairo

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES


Interim condensed consolidated statement of financial position - At 30 June 2022

(All amounts in Egyptian Pounds)	Note	30 June 2022	31 December 2021
Assets			
Non-current assets			
Fixed assets	4	1,401,609,032	1,351,725,422
Right-of-use assets	5	161,288,108	174,691,615
Goodwill		369,263,334	369,263,334
Other intangible assets		55,217,751	56,252,393
Investments in associates		2,178,321	2,178,301
Paid under investments purchased		24,173,000	5,673,000
Total non-current assets		2,013,729,546	1,959,784,065
Current assets			
Inventories	6	69,961,098	51,301,188
Trade receivables	8	443,039,181	383,324,030
Due from related parties	9	1,975,407	530,300
Debtors and other debit balances	10	143,546,126	191,702,419
Financial assets at amortized cost - treasury bills	11	109,455,990	677,072,914
Cash on hands and at banks	12	218,919,987	168,906,593
Total current assets		986,897,789	1,472,837,444
Total assets		3,000,627,335	3,432,621,509
Equity and liabilities			
Equity			
Share capital		800,000,000	800,000,000
Treasury Shares	23	(645,888,947)	(4,152,742)
Retained earnings		1,354,599,943	1,269,995,272
Employees stock ownership plan		16,579,882	8,289,941
Reserves		317,561,111	302,942,579
Equity attributable to the Company's owners		1,842,851,989	2,377,075,050
Non-controlling interests	13	129,508,441	120,742,065
Total equity		1,972,360,430	2,497,817,115
Liabilities			
Non-current liabilities			
Lease liabilities	14	163,135,389	172,713,165
Deferred tax liabilities	7	82,598,007	81,809,839
Purchased investment liability		38,670,000	31,760,000
Total non-current liabilities		284,403,396	286,285,004
Current liabilities			
Banks overdraft	15	160,148,412	60,627,560
Provisions		19,315,547	21,917,498
Trade and other credit balances	16	482,105,807	461,032,559
Lease liabilities	14	40,711,443	38,742,917
Current income tax liabilities		41,582,300	66,198,856
Total current liabilities		743,863,509	648,519,390
Total liabilities		1,028,266,905	934,804,394
Total liabilities and equity		3,000,627,335	3,432,621,509

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

- Limited review report is attached


Mr. Ahmed Gamal
Group CFO


Dr. Ahmed Ezz Eldin Mahmoud
CEO & Managing Director


Mr. Ahmed Adel Badreldin
Non Executive Chairman

18 August 2022
Cairo



CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Interim condensed consolidated statement of profit or loss
For the six months period ended 30 June 2022

(All amounts in Egyptian Pounds)

	Note	Six months ended 30 June		Three months ended 30 June	
		2022	2021	2022	2021
Operating revenue	17	1,241,680,335	1,276,752,529	604,774,950	643,589,357
Less:					
Operating costs	18	(827,588,349)	(796,064,219)	(412,634,008)	(404,098,448)
Gross profit		414,091,986	480,688,310	192,140,942	239,490,909
Add / (Less):					
General and administrative expenses	19	(183,721,039)	(160,898,471)	(91,695,322)	(79,167,237)
Impairment of financial assets	20	(17,959,101)	(38,969,272)	(7,913,062)	(28,443,397)
Provisions		(8,894,861)	(11,322,744)	(4,446,961)	(1,686,869)
Costs of acquisition activities		(918,990)	(6,861,358)	(124,468)	(1,553,324)
Other income		1,929,441	5,094,351	64,426	205,044
Finance income		31,417,201	25,856,088	10,745,330	13,220,583
Finance expenses		(16,358,839)	(14,851,400)	(9,009,022)	(8,817,397)
Profit for the period before income tax		219,585,798	278,735,504	89,761,863	133,248,312
Current tax		(42,323,069)	(78,042,297)	(15,051,105)	(40,624,694)
Deferred tax		(788,168)	1,324,480	(658,549)	1,456,206
Profit after income tax		176,474,561	202,017,687	74,052,209	94,079,824
Profit for:					
Owners of the parent company		164,426,846	191,883,619	68,443,915	90,574,706
Non-controlling interests	13	12,047,715	10,134,068	5,608,294	3,505,118
Profit after income tax		176,474,561	202,017,687	74,052,209	94,079,824
Earning per share	21	0.11	0.12	0.04	0.06

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Interim condensed consolidated statement of comprehensive income
For the six months period ended 30 June 2022

(All amounts in Egyptian Pounds)

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Profit for the period	176,474,561	202,017,687	74,052,209	94,079,824
Other comprehensive income	-	-	-	-
Comprehensive income for the period	176,474,561	202,017,687	74,052,209	94,079,824
Profit for:				
Owners of the parent Company	164,426,846	191,883,619	68,443,915	90,574,706
Non-controlling interests	12,047,715	10,134,068	5,608,294	3,505,118
Profit after income tax	176,474,561	202,017,687	74,052,209	94,079,824

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

**Interim condensed consolidated statement of changes in equity
For the six months period ended 30 June 2022**

(All amounts in Egyptian Pounds)

	Share capital	Treasury shares	Reserves	Retained earnings	Employees stock ownership Plan	Shareholders equity of the parent Company	Non-controlling interest	Total equity
Balance at 31 December 2020 (as previously published)	800,000,000	-	281,336,162	984,874,111	-	2,066,210,273	107,725,535	2,173,935,808
New EAS adoption	-	-	-	(45,013,349)	-	(45,013,349)	(8,945,528)	(53,958,877)
Balance at 1 January 2021	800,000,000	-	281,336,162	939,860,762	-	2,021,196,924	98,780,007	2,119,976,931
Dividends	-	-	-	(45,444,024)	-	(45,444,024)	(2,197,732)	(47,641,756)
Treasury shares	-	(46,612,865)	-	-	-	(46,612,865)	-	(46,612,865)
Reserves formed	-	-	10,933,804	(11,666,617)	-	(732,813)	732,813	-
Comprehensive income for the period	-	-	-	191,883,619	-	191,883,619	10,134,068	202,017,687
Balance at 30 June 2021	800,000,000	(46,612,865)	292,269,966	1,074,633,740	-	2,120,290,841	107,449,156	2,227,739,997
Balance at 1 January 2022	800,000,000	(4,152,742)	302,942,579	1,269,995,272	8,289,941	2,377,075,050	120,742,065	2,497,817,115
Dividends	-	-	-	(63,825,164)	-	(63,825,164)	(4,659,818)	(68,484,982)
Employees stock ownership Plan	-	-	-	-	8,289,941	8,289,941	-	8,289,941
Treasury shares	-	(641,736,205)	-	-	-	(641,736,205)	-	(641,736,205)
Reserves formed	-	-	14,618,532	(15,997,011)	-	(1,378,479)	1,378,479	-
Comprehensive income for the period	-	-	-	164,426,846	-	164,426,846	12,047,715	176,474,561
Balance at 30 June 2022	800,000,000	(645,888,947)	317,561,111	1,354,599,943	16,579,882	1,842,851,989	129,508,441	1,972,360,430

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Interim condensed consolidated statement of cash flows
For the six months period ended 30 June 2022

(All amounts in Egyptian Pounds)	Note	30 June 2022	30 June 2021
<u>Cash flows from operating activities</u>			
Profit before tax		219,585,798	278,735,504
Adjustments to reconcile net income to cash flows from operating activities			
Fixed assets depreciation	4	63,379,480	54,508,999
Right of use depreciation		13,066,122	12,789,096
Intangible assets amortiation		7,944,642	7,944,643
Profit from sale of fixed assets		(209,552)	(39,302)
Impairment of inventories	6	(188,798)	373,890
Impairment of trade receivables	8	(35,010,305)	41,064,134
Reversal of impairment of cash	12	77,828	(2,137,753)
Provisions		8,894,861	11,322,644
Employees stock ownership Plan		8,289,941	-
Interests and commissions - Overdraft		3,195,434	3,422,255
Interests and commissions - Lease		13,065,146	11,380,590
Interest income		(27,850,269)	(25,855,083)
Gain in investments in associates		-	(81,899)
Operating profits before changes in assets and liabilities		274,240,328	393,427,718
Changes in assets and liabilities			
Change in inventories		(18,471,112)	2,676,571
Change in trade receivables		(24,704,848)	(43,648,999)
Change in due from related parties		(1,445,107)	(221,140)
Change in debtors and other debit balances		55,020,557	38,247,721
Change in due to related parties		-	(597,889)
Change in Creditors and other credit balances		16,783,539	(10,209,797)
Provision used		(11,496,811)	(10,535,857)
Income tax paid		(66,939,625)	(51,918,117)
Net cash flows generated from (used in) operating activities		222,986,921	317,220,211
<u>Cash flows from investing activities</u>			
Payments for purchase fixed assets		(41,466,782)	(34,362,520)
Payments for projects under construction		(73,025,240)	(86,855,309)
Prepayments for purchasing fixed assets		(1,110,781)	(20,402,894)
Proceeds from sale of fixed assets		1,438,484	196,236
Payments under investments in subsidiaries		-	-
Payments under investments in associates		(200)	-
Payments for investments		(18,500,000)	(305,687,787)
Interests received		22,096,788	20,356,560
Net cash flows used in investing activities		(110,567,731)	(426,755,714)
<u>Cash flows from financing activities</u>			
Payments of lease liabilities		(6,667,878)	(28,995,182)
Treasury shares		(641,736,205)	(46,612,865)
Proceeds from bank overdraft		597,009,334	219,261,355
Payment of borrowings and bank overdraft		(497,488,482)	(80,811,495)
Dividends paid		(65,088,788)	(47,157,098)
Interests and commissions paid		(15,366,879)	(15,464,779)
Net cash flows generated from (used in) financing activities		(629,338,898)	219,936
Change in cash and cash equivalents during the period		(516,919,708)	(109,315,567)
Cash and cash equivalents at the beginning of the period		847,525,002	550,517,584
Cash and cash equivalents at the end of the period	12	330,605,294	441,202,017

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

1. Introduction

Cleopatra Hospital Company "the Parent Company" (formerly Lasheen & Co.) was incorporated as a limited partnership on July 19, 1979.

The decision of the head of Investment Authority No. 4092 of 2005 was issued on 27 June 2005 authorising the conversion of the legal type of Cleopatra Hospital from a "limited partnership" into Cleopatra Hospital Company "S.A.E." in accordance with the provisions of Law No. (8) Of 1997 and Law No. (95) Of 1992. The Company is listed on the Egyptian Stock Exchange.

The purpose of the Company and its subsidiaries (together referred to as the "Group") is to establish a private hospital to provide modern and high-quality health and medical services and to provide medical care to inpatients. The company may have an interest or may participate in any way with companies or others that carry out business like its business in Egypt or abroad. The company may also acquire, merge or attach to these facilities.

The Company is located at 39, 41 Cleopatra Street, Heliopolis, Cairo.

These interim condensed consolidated financial statements have been approved for issuance by the Board of Directors of the Parent Company on 18 August 2022.

2. Basis of preparation

A. Statement of Compliance

This interim condensed consolidated financial statements for the three-month reporting period ended 30 June 2022 have been prepared in accordance with Egyptian Accounting Standard 30 "Interim Financial Reporting".

This interim condensed consolidated financial information does not include all the disclosures that would normally be disclosed in preparing the full annual financial statements. Therefore, this interim condensed consolidated financial information should be read with the annual consolidated financial statements of the Group on 31 December 2021.

The accounting policies used in preparing this interim condensed financial information are consistent with those used in preparing the annual financial statements for the fiscal year ending on 31 December 2021 and the fiscal periods Comparison.

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

Statement of Compliance (continued)

The interim condensed consolidated financial statements include the financial statements of the following subsidiaries:

	Country of incorporation	Percentage of ownership 30 June 2022	Percentage of ownership 31 December 2021
Al-Shorouk Hospital Company S.A.E.	Egypt	99.99%	99.99%
Nile Badrawi Hospital Company S.A.E.	Egypt	99.99%	99.99%
Cairo Specialised Hospital Company S.A.E.	Egypt	56,46%	56,46%
		20%	20%
CHG for Medical Services Company S.A.E.	Egypt	(preference shares)	(preference shares)
CHG Pharma for Pharmacies Management Company S.A.E.	Egypt	98%	98%
CHG for hospitals S.A.E.	Egypt	99.99%	99.99%
Bedaya El Gedida Company for Medical Centers and Hospitals S.A.E.	Egypt	99.99%	99.99%
CHG Sky hospitals S.A.E.	Egypt	99.99%	99.99%

B. Functional and presentation currency

Items included in the interim consolidated financial statements are measured using the currency of the primary economic environment in which the Group operates ('the functional currency'). The interim consolidated financial statements are presented in Egyptian Pounds (EGP), which is the Group's functional and presentation currency.

C. Use of estimates and judgements

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

Significant judgments used by management in applying the group's accounting policies and the main sources of estimation uncertainty are the same as those disclosed in the latest consolidated financial statements and for the financial year ended 31 December 2021.

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the consolidated interim financial statements – For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

3. Segment reporting

Business segments are reported in line with the reports provided internally to the senior management, which makes decisions related to resources allocation and evaluation of segments' performance in the Group. The senior management is represented in Group's executive management committee. The segment reports are provided to the Group based on each company, as each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the period ended 30 June 2022 for each segment:

Statement of financial position	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawi Hospital	Al Shorouk Hospital	CHG				Bedaya El Gedida for Medical Centers and Hospitals	CHG Sky Consolidation hospital.	Total		
					CHG for Medical Services	Pharma for pharmacies management	CHG for Hospitals	Queens Hospitals				AI Kateb Hospitals	adjustment
Non-current assets	1,520,220,308	330,703,247	257,107,242	243,201,474	38,211,258	3,458,653	-	69,365,267	137,494,241	90,421,540	(676,453,684)	2,013,729,546	
Current assets	347,847,154	153,170,860	167,173,852	209,578,174	20,885,847	10,974,195	25,140,658	84,394,614	36,772,622	52,340,904	35,000,000	(156,381,091)	986,897,789
Total assets	1,868,067,462	483,874,107	424,281,094	452,779,648	59,097,105	14,432,848	25,140,658	153,759,881	174,266,863	142,762,444	35,000,000	(832,834,775)	3,000,627,335
Current liabilities	407,421,038	130,024,322	88,430,480	94,825,280	91,591,218	17,821,411	992,002	33,995,657	34,533,491	15,808,649	-	(171,580,039)	743,863,509
Non-current liabilities	40,986,542	12,448,300	20,956,542	24,685,671	36,943,526	4,243,032	-	67,467,395	3,455,366	25,842,564	-	47,374,458	284,403,396
Total Liabilities	448,407,580	142,472,622	109,387,022	119,510,951	128,534,744	22,064,443	992,002	101,463,052	37,988,857	41,651,213	-	(124,205,581)	1,028,266,905
Statement of profit or loss:													
Operating revenue	491,444,933	237,955,847	177,666,255	208,378,345	39,592,377	20,952,878	-	30,392,911	17,512,570	30,279,612	-	(12,495,393)	1,241,680,335
Operating costs	(276,251,845)	(165,032,281)	(136,927,691)	(146,037,150)	(31,492,885)	(20,109,788)	-	(18,884,860)	(25,340,299)	(18,469,956)	-	10,958,406	(827,588,349)
Gross profit	215,193,088	72,923,566	40,738,564	62,341,195	8,099,492	843,090	-	11,508,051	(7,827,729)	11,809,656	-	(1,536,987)	414,091,986
Other expenses and revenues	(89,214,078)	(43,900,118)	(28,621,727)	(36,725,220)	(9,545,261)	(1,577,138)	(235,649)	(5,254,538)	(6,323,198)	(15,399,224)	-	(821,276)	(237,617,427)
Profit for the period	125,979,010	29,023,448	12,116,837	25,615,975	(1,445,769)	(734,048)	(235,649)	6,253,513	(14,150,927)	(3,589,568)	-	(2,358,263)	176,474,561
Other Items													
Capital expenditure	25,645,195	49,235,510	15,776,283	15,403,313	268,209	6,599	-	365,943	4,148,662	3,642,308	-	-	114,492,022
Fixed assets depreciation	18,559,437	12,535,065	9,686,199	10,430,577	109,066	1,456	-	1,646,759	3,863,407	2,259,749	-	4,287,765	63,379,480

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Notes to the consolidated interim financial statements - For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

Segment reporting (continued)

Below is a summary of each segment, which is presented for the year ended 31 December 2021 for each segment:

Statement of financial position	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawi Hospital	Al Shorouk Hospital	CHG for Medical Services	CHG Pharma for pharmacies management	CHG for Hospitals	Queens Hospitals	Al Kateb Hospitals	Bedaya El Gedida for Medical Centers and Hospitals	Consolidation adjustment	Total
Non-current assets	1,460,626,912	294,687,131	253,669,733	237,447,580	49,061,664	3,809,120	-	72,791,123	134,865,621	90,287,957	(637,462,776)	1,959,784,065
Current assets	791,225,113	179,127,975	159,423,841	188,924,507	20,212,049	9,090,455	25,456,940	106,725,556	63,940,470	44,503,263	(115,792,725)	1,472,837,444
Total assets	2,251,852,025	473,815,106	413,093,574	426,372,087	69,273,713	12,899,575	25,456,940	179,516,679	198,806,091	134,791,220	(753,255,501)	3,432,621,509
Current liabilities	241,752,965	138,147,695	84,073,028	87,690,796	88,785,291	15,220,662	911,972	66,870,655	43,577,783	11,362,104	(129,873,561)	648,519,390
Non-current liabilities	38,015,589	13,032,679	22,107,912	23,308,314	48,480,290	4,576,460	-	66,602,710	3,382,956	18,596,421	48,181,673	286,285,004
Total Liabilities	279,768,554	151,180,374	106,180,940	110,999,110	137,265,581	19,797,122	911,972	133,473,365	46,960,739	29,958,525	(81,691,888)	934,804,394
Statement of profit or loss:												
Operating revenue	935,166,243	458,923,126	375,285,656	379,473,301	74,520,431	37,365,554	1,193,771	164,383,486	110,217,897	49,272,776	(36,515,379)	2,549,286,862
Operating costs	(523,192,530)	(308,912,823)	(268,928,355)	(266,151,463)	(63,104,174)	(35,782,687)	-	(77,718,776)	(77,201,230)	(30,030,881)	32,401,297	(1,618,621,622)
Gross profit	411,973,713	150,010,303	106,357,301	113,321,838	11,416,257	1,582,867	1,193,771	86,664,710	33,016,667	19,241,895	(4,114,082)	930,665,240
Other expenses and revenues	(184,257,324)	(86,719,952)	(71,000,261)	(67,987,355)	(21,703,339)	(2,744,419)	(379,696)	(33,963,941)	(21,063,178)	(30,310,011)	136,364	(519,993,112)
Profit for the year	227,716,389	63,290,351	35,357,040	45,334,483	(10,287,082)	(1,161,552)	814,075	52,700,769	11,953,489	(11,068,116)	(3,977,718)	410,672,128
Other Items												
Capital expenditure	57,220,004	131,756,662	36,713,943	21,194,874	581,728	17,430	-	2,830,097	8,004,500	6,277,157	-	264,596,395
Fixed assets depreciation	34,827,246	24,387,131	16,828,440	17,837,994	106,399	1,493	-	3,171,302	3,987,360	4,159,763	8,575,523	113,882,651

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Notes to the consolidated interim financial statements - For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

Segment reporting (continued)

Below is a summary of each segment, which is presented for the period ended 30 June 2021 for each segment:

Statement of financial position	CHG							New Bedaya company for medical centers and hospitals	Consolidated adjustment	Total		
	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawi Hospital	Al Shorouk Hospital	CHG for Medical Services	Pharma for pharmacies management	CHG for Hospitals				Queens Hospitals	Al Kateb Hospitals
Non-current assets	1,581,452,997	241,329,001	238,433,711	237,005,288	45,462,736	4,132,094	-	75,853,190	9,675,085	92,759,806	(622,973,541)	1,903,130,367
Current assets	675,877,875	167,410,089	169,728,404	157,317,784	23,106,841	20,285,797	25,455,658	94,196,036	66,254,303	36,337,345	(125,191,505)	1,310,778,627
Total assets	2,257,330,872	408,739,090	408,162,115	394,323,072	68,569,577	24,417,891	25,455,658	170,049,226	75,929,388	129,097,151	(748,165,046)	3,213,908,994
Current liabilities	301,317,508	110,324,080	94,632,356	79,250,473	86,271,584	25,442,375	856,135	78,853,649	38,190,635	10,582,008	(138,686,029)	687,034,774
Non-current liabilities	50,024,370	9,891,793	20,637,265	24,448,188	46,441,905	4,746,028	-	67,135,107	4,086,939	11,074,805	60,647,823	299,134,223
Total liabilities	351,341,878	120,215,873	115,269,621	103,698,661	132,713,489	30,188,403	856,135	145,988,756	42,277,574	21,656,813	(78,038,206)	986,168,997
Statement of profit or loss:												
Operating revenue	450,063,217	224,667,580	190,996,841	183,861,272	35,748,766	15,973,164	1,192,489	102,253,604	76,200,244	20,226,725	(24,431,373)	1,276,752,529
Operating costs	(253,253,110)	(153,196,716)	(134,734,379)	(126,397,654)	(30,148,633)	(14,022,995)	-	(45,322,123)	(46,942,639)	(13,819,795)	21,773,825	(796,064,219)
Gross profit	196,810,107	71,470,864	56,262,462	57,463,618	5,600,133	1,950,169	1,192,489	56,931,481	29,257,605	6,406,930	(2,657,548)	480,688,310
Other expenses and revenues	(93,879,159)	(42,292,029)	(34,925,563)	(37,138,573)	(12,039,258)	(1,906,531)	(323,859)	(26,213,557)	(15,383,957)	(14,867,412)	(299,275)	(278,970,623)
Profit for period	102,930,948	29,178,835	21,336,899	20,325,045	(6,439,125)	43,638	868,630	30,717,924	13,873,648	(8,460,482)	(2,358,273)	202,017,687
Other Items												
Capital expenditure	25,993,585	67,395,389	11,316,943	7,658,526	204,988	10,590	-	1,054,621	1,911,646	5,671,541	-	121,217,829
Fixed assets depreciation	14,789,169	12,030,720	7,853,268	8,787,784	32,532	-	-	1,501,133	3,189,237	2,037,398	4,287,758	54,508,999

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Notes to the consolidated interim financial statements - For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

4. Fixed assets

	Lands	Machinery, equipment and devices	Furniture	Buildings	Vehicles	Computers	Projects under construction	Total
On 1 January 2021								
Cost	173,240,262	626,167,940	105,792,062	549,004,858	15,691,737	102,687,785	99,720,766	1,672,305,410
Accumulated depreciation	-	(261,113,137)	(38,054,959)	(114,997,947)	(7,328,973)	(45,614,534)	-	(467,109,550)
Net book value	173,240,262	365,054,803	67,737,103	434,006,911	8,362,764	57,073,251	99,720,766	1,205,195,860
Year ended 31 December 2021								
Opening net book value	173,240,262	365,054,803	67,737,103	434,006,911	8,362,764	57,073,251	99,720,766	1,205,195,860
Additions	-	48,252,892	19,125,873	868,488	4,902,800	24,324,199	167,122,143	264,596,395
Disposals	-	(8,189,448)	(1,349,937)	(106,884)	(76,000)	(11,528)	-	(9,733,797)
Write-off	-	(4,179,426)	(967,569)	-	-	(572,134)	-	(5,719,129)
Transfers from projects under construction	-	12,955,477	12,375,644	108,837,042	-	10,055,925	(144,224,088)	-
Depreciation for the year	-	(51,598,344)	(14,197,713)	(20,513,110)	(2,943,291)	(24,630,193)	-	(113,882,651)
Accumulated depreciation of disposal	-	8,462,378	2,125,592	23,103	76,000	581,671	-	11,268,744
Closing net book value	173,240,262	370,758,332	84,848,993	523,115,550	10,322,273	66,821,191	122,618,821	1,351,725,422
On 31 December 2021								
Cost	173,240,262	675,007,435	134,976,073	658,603,504	20,518,537	136,484,247	122,618,821	1,921,448,879
Accumulated depreciation	-	(304,249,103)	(50,127,080)	(135,487,954)	(10,196,264)	(69,663,056)	-	(569,723,457)
Net book value at the year end	173,240,262	370,758,332	84,848,993	523,115,550	10,322,273	66,821,191	122,618,821	1,351,725,422
On 30 June 2022								
Opening net book value	173,240,262	370,758,332	84,848,993	523,115,550	10,322,273	66,821,191	122,618,821	1,351,725,422
Additions	-	23,055,108	11,600,241	1,410,164	-	5,401,269	73,025,240	114,492,022
Disposals	-	(6,278,998)	(1,443,677)	(220,000)	(770,000)	(180,777)	-	(8,893,452)
Transfers from projects under construction	-	349,406	678,806	2,482,921	-	1,201,145	(4,712,278)	-
Depreciation for the period	-	(27,442,335)	(8,833,739)	(11,189,125)	(2,702,648)	(13,211,633)	-	(63,379,480)
Accumulated depreciation of disposal	-	5,749,207	1,400,731	-	336,875	177,707	-	7,664,520
Balance on 30 June 2022	173,240,262	366,190,720	88,251,355	515,599,510	7,186,500	60,208,902	190,931,783	1,401,609,032
Cost	173,240,262	692,132,951	145,811,443	662,276,589	19,748,537	142,905,884	190,931,783	2,027,047,449
Accumulated depreciation	-	(325,942,231)	(57,560,088)	(146,677,079)	(12,562,037)	(82,696,982)	-	(625,438,417)
Net book value at the period end	173,240,262	366,190,720	88,251,355	515,599,510	7,186,500	60,208,902	190,931,783	1,401,609,032

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

5. Right of use assets

The right of use represents lease contracts related to buildings, machinery and medical equipment and was measured at a carrying amount as if the standard had been applied since the inception of the lease, however discounted using the borrowing rate to the lessee at the date of application, and it is subsequently amortized over the life of the lease using the straight-line method.

	30 June 2022	31 December 2021
Machinery and equipment		
Beginning balance for the period / year	16,818,578	18,824,508
Additions during the period / year	-	-
Depreciation during the period / year	(1,047,667)	(2,005,930)
Total – machinery and equipment	15,770,911	16,818,578
Buildings		
Beginning balance for the period / year	157,873,037	-
The impact of the first adoption standard no. 49 “Leases”	-	161,848,949
Adjustments	(3,533,554)	
Additions for the period / year	3,196,168	19,974,500
Depreciation for the period / year	(12,018,455)	(23,950,412)
Total	145,517,197	157,873,037
	161,288,108	174,691,615

Lease payments are discounted using the interest rate implicit in the lease. If this rate cannot be determined, the lessee's borrowing rate is used, which is the rate that the lessee would have to pay to borrow the money needed to obtain an asset of similar value in a similar economic environment with similar terms and conditions. An average interest rate of 11.15% was used. For financing lease contracts for buildings 12.15% and 16.15% for financing lease contracts for medical machinery and equipment

6. Inventories

	30 June 2022	31 December 2021
Medicine inventory	31,089,837	21,709,850
Medical supply inventory	34,971,994	26,439,233
Maintenance and spare parts inventory	1,459,967	1,647,600
Stationary inventory	1,393,346	1,142,632
Hospitality inventory	1,145,402	655,754
Food and beverage inventory	180,726	175,091
	70,241,272	51,770,160
Less: Impairment of inventory	(280,174)	(468,972)
	69,961,098	51,301,188

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

Inventories (continued)

Movement in the provision for inventory is as follows:

	30 June 2022	31 December 2021	30 June 2021
Balance on 1 January	468,972	466,550	466,550
Provisions formed during the period / year	103,210	1,312,118	737,734
Provisions no longer required during the period / year	(292,008)	(1,049,474)	(85,022)
Write-offs during the period / year	-	(260,222)	(278,822)
Balance at the end of the period / year	280,174	468,972	840,440

7. Deferred tax

The movement of deferred tax assets / (liabilities) during the period:

	Balance at 1 January 2022 (Liability)	(Expense) income charged during the period	Balance at 30 June 2022 (Liability)
Liabilities			
Fixed assets	(44,281,274)	(1,273,850)	(45,555,124)
Fixed assets - fair value impact	(38,359,550)	964,747	(37,394,803)
Intangible assets - fair value impact	(9,979,650)	-	(9,979,650)
Total liabilities	(92,620,474)	(309,103)	(92,929,577)
Assets			
Provision (excluded claims provisions)	3,347,063	(479,065)	2,867,998
Subsidiaries accumulated losses	7,463,572	-	7,463,572
Net deferred tax – Liability	(81,809,839)	(788,168)	(82,598,007)

The movement of deferred tax assets / (liabilities) during the period:

	Balance at 1 January 2021 (Liability)	(Expense) income charged during the year	Balance at 31 December 2021 (Liability)
Liabilities			
Fixed assets	(38,636,541)	(5,644,733)	(44,281,274)
Fixed assets - fair value impact	(40,289,043)	1,929,493	(38,359,550)
Intangible assets - fair value impact	(9,979,650)	-	(9,979,650)
Total liabilities	(88,905,234)	(3,715,240)	(92,620,474)
Assets			
Provision (excluded claims provisions)	3,547,300	(200,237)	3,347,063
Subsidiaries accumulated losses	7,463,572	-	7,463,572
Net deferred tax – Liability	(77,894,362)	(3,915,477)	(81,809,839)

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

8. Trade receivables

	30 June 2022	31 December 2021
Due from customers	522,508,312	502,010,165
Income from inpatients	15,360,141	11,153,442
	537,868,453	513,163,607
Less:		
Expected credit losses in the trade receivables balances	(94,829,272)	(129,839,577)
	443,039,181	383,324,030

The income from inpatients comprises of the revenues that have not been billed at the financial position date in exchange for their stay while the procedures of the medical services have not been completed. Such income is calculated net of the amounts collected in advance during the period of their stay.

The Group applies the EAS no. (47) simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

The expected loss rates are based on the payment profiles of customers over a period of 36 month before each financial position date and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Group has identified the GDP and the unemployment rate of the countries in which it sells services to be the most relevant factors, and accordingly adjusts the historical loss rates based on expected changes in these factors.

The credit loss allowance for trade receivables is determined according to the provision matrix presented in the table below. The provision matrix is based on the number of days that an asset is past due, with adjusting it.

	30 June 2022			
	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
Trade receivables				
- Current until less than 30 days overdue	0,3%	363,752,877	1,271,722	362,481,154
- 30 to 60 days overdue	4%	28,419,959	1,009,032	27,410,928
- 61 to 90 days overdue	8%	15,451,813	1,196,100	14,255,713
- 91 to 120 days overdue	13%	14,535,648	1,944,643	12,591,005
- 121 to 360 days overdue	38%	30,966,738	11,664,814	19,301,923
- 361 to 720 days overdue	49%	13,692,832	6,694,375	6,998,457
- More than 720 days	100%	71,048,585	71,048,586	-
Total		537,868,453	94,829,272	443,039,181

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

**Notes to the interim condensed consolidated financial statements
For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

8- Trade receivables (continued)

	31 December 2021			
	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
<u>Trade receivables</u>				
- Current until less than 30 days overdue	1%	313,356,068	1,970,326	311,385,742
- 31 to 60 days overdue	5%	34,286,882	1,747,469	32,539,413
- 61 to 90 days overdue	11%	18,700,626	2,027,866	16,672,760
- 91 to 120 days overdue	23%	9,174,368	2,114,843	7,059,525
- 121 to 360 days overdue	57%	28,980,899	16,485,495	12,495,404
- 361 to 720 days overdue	70%	10,477,794	7,306,608	3,171,186
- More than 720 days	100%	98,186,970	98,186,970	-
Total		513,163,607	129,839,577	383,324,030

Movement in the provision for trade receivables impairments is as follows:

	30 June 2022	31 December 2021	30 June 2021
Balance at the beginning of the period / year	129,839,577	125,326,367	125,326,367
The impact of the first adoption standard no.47 “Financial Instruments”	-	11,289,842	11,289,842
Provisions formed during the period / year	24,130,716	105,383,023	77,520,869
Provision used during the period / year	(52,891,578)	(52,753,994)	(36,413,844)
Provision no longer required during period /year	(6,249,443)	(59,405,661)	(42,891)
Ending balance at the end of period / year	94,829,272	129,839,577	177,680,343

9. Related Parties transactions:

During the period / year the Group made transactions with certain related parties. The Balances with related parties at the financial statements date as well as the transactions during the period / year were as follows:

Balances of financial position

(Related parties)	Nature of transaction	Balance due from / (to) related parties 30 June 2022	Balance due from / (to) related parties 31 December 2021
Other parties	Expenses paid on behalf of the Company	1,975,407	530,300
		1,975,407	530,300

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

10. Debtors and other debit balances

	30 June 2022	31 December 2021
Advances to suppliers	95,420,006	67,780,202
Prepaid expenses	20,385,159	7,592,208
Withholding taxes	11,727,591	11,494,414
Deposits with others	5,133,754	5,105,318
Employee’s custodies	846,989	648,595
Accrued income	257,332	421,907
Treasury shares debtors	-	84,428,630
Other debtors	9,778,079	14,233,929
	143,548,910	191,705,203
Less: Impairment of other debit balances	(2,784)	(2,784)
	143,546,126	191,702,419

The movement of the debtor’s impairment during the period / year is as follows:

	30 June 2022	31 December 2021	30 June 2021
Balance at the beginning of the period / year	2,784	42,202	42,202
No longer required of the period / year	-	(39,418)	-
Balance at the end of the period / year	2,784	2,784	42,202

11. Financial assets at amortized cost - Treasury bills

	30 June 2022	31 December 2021
Treasury Bills (Maturity 61 days)	80,000,000	636,400,000
Treasury bills (Maturity 91 days)	-	45,450,070
Treasury bills (Maturity 30 days)	30,000,000	-
Less: Unearned revenue	(544,010)	(4,777,156)
	109,455,990	677,072,914

Treasury bills are entitled to a constant annual return of 9.4% after taxes on 30 June 2022 (31 December: 8.4% and 9.6%).

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

12. Cash on hand and at banks

	30 June 2022	31 December 2021
Current accounts	198,591,389	151,913,259
Time deposit	17,974,840	15,036,965
Cash on hand	3,977,075	3,501,864
Less:		
Cash and cash equivalents impairment	(1,623,317)	(1,545,495)
	218,919,987	168,906,593

The movement in the impairment of cash and cash equivalents is as follows:

	30 June 2022	31 December 2021	30 June 2021
Balance at the beginning of the period / year	1,545,489	-	-
The impact of the first adoption standard no.47 “Financial Instruments”	-	4,492,746	4,492,746
Provisions formed during the period / year	695,373	246,880	-
Provision no longer required during period /year	(617,545)	(3,194,131)	(2,137,753)
Ending balance at the end of period / year	1,623,317	1,545,495	2,354,993

For preparation of the cash flow statements, cash and cash equivalents consist of:

	30 June 2022	30 June 2021
Cash and bank balances before deducting the expected credit losses	220,543,304	316,692,662
Treasury bills with maturities of 3 months or less	109,455,990	129,002,101
	-	(4,492,746)
Total	329,999,294	441,202,017

(A) Classification within cash and cash equivalent

Time deposits held at banks presented as cash and cash equivalents if they are due for a period of six months or less from the date of deposit and are repayable with a notice of 24 hours without loss of interest. Treasury bills under cash and cash equivalents have original maturities of no more than six months from the date of acquisition, are easily convertible into known amounts of cash and are subject to an insignificant risk of changes in value.

The Company's cash and bank balances are held with reputable financial institutions with credit ratings from Moody's and Standard & Poor's from B to B2.

(B) Treasury bills

Investment in treasury bills with a maturity period of one to two months.

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

13. Non-controlling interests

	Capital	Reserves	Retained earnings	NCI share in acquisition adjustments	Total
Balance on 31 December 2020	34,074,639	7,984,596	65,546,116	120,184	107,725,535
Effect of changes in accounting standards	-	-	(8,945,528)	-	(8,945,528)
Balance on 1 January 2021	34,074,639	7,984,596	56,600,588	120,184	98,780,007
Employee profit share	-	-	(2,197,732)	-	(2,197,732)
Legal reserve	-	732,813	-	-	732,813
Comprehensive income for the year	-	-	23,426,977	-	23,426,977
Balance on 31 December 2021	34,074,639	8,717,409	77,829,833	120,184	120,742,065
Balance on 1 January 2022	34,074,639	8,717,409	77,829,833	120,184	120,742,065
Employee profit share	-	-	(4,659,818)	-	(4,659,818)
Legal reserve	-	1,378,479	-	-	1,378,479
Comprehensive income for the period	-	-	12,047,715	-	12,047,715
Balance on 30 June 2022	34,074,639	5,436,070	89,877,548	120,184	129,508,441

14. Lease liabilities

The lease liabilities represent the present value of the lease obligations related to medical equipment that one of the group companies obtained in exchange for lease contracts for buildings, and it was measured at the present value of the contractual lease payments discounted at an implied rate of return of 12.15%, 16.65% and 11.15%.

	30 June 2022	31 December 2021
The undiscounted value of the lease obligations as follows:		
During the period / year	40,696,178	40,045,267
More than a year	324,628,529	345,574,165
	365,324,707	385,619,432
The present value of the lease obligations as follows:		
During the period / year	40,711,443	38,742,917
More than a year	163,135,389	172,715,165
Balance	203,846,832	211,458,082

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

14- Lease liabilities (continued)

	30 June 2022	31 December 2021
Lease liabilities shown as on 31 December 2021	211,458,082	13,275,078
The impact of the first adoption standard no. 49 “Lease contracts”	-	197,425,332
Adjustments during the period / year	(3,839,540)	-
Lease liabilities on 1 January 2022	207,618,542	210,700,410
Additions during the period / year	2,896,168	19,974,500
Add: Interest formed during the period / year	13,065,146	24,506,126
Deduct: Payments during the period / year	(19,733,024)	(43,722,954)
Lease liabilities on 30 June 2022	203,846,832	211,458,082

15. Bank’s overdraft

The group obtained total credit limits in the form of overdrafts from banks in order to finance working capital at an interest rate of 0.1% in addition to the announced borrowing rate from the Central Bank. The total available credit limits amounted to 280 million EGP and the withdrawn value of these credit limits on 30 June 2022 equals 160,148,412 EGP (31 December 2021: 60,627,560).

16. Trade and other credit balances

	30 June 2022	31 December 2021
Suppliers and notes payable	234,632,534	227,368,417
Accrued expenses	184,001,709	173,697,850
Social insurance	7,849,998	5,787,212
Employee dividends payable	5,905,259	3,925,487
Other creditors	49,716,307	50,253,593
	482,105,807	461,032,559

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

17. Operating revenue

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Accommodation and medical supervision revenue	267,621,426	342,358,809	124,084,926	170,929,020
Surgeries revenue	249,945,796	226,268,364	128,927,356	116,371,702
Laboratories revenue	140,770,871	151,046,069	65,962,424	76,421,321
Outpatient clinics revenue	136,387,501	128,164,737	65,372,252	65,134,066
Radiology revenue	88,741,868	100,324,287	43,250,449	50,226,783
Cardiac catheterization revenue	94,426,828	97,153,342	46,597,503	47,258,996
Service charge revenue	88,368,356	87,343,393	43,314,722	43,569,913
Pharmacy revenue	64,513,617	51,366,482	31,130,193	26,795,150
Emergency revenue	42,792,126	38,923,802	21,871,012	20,500,326
Revenues of oncology centre	19,162,516	17,724,197	8,765,605	8,622,752
Physiotherapy revenue	11,922,431	9,483,190	6,065,080	4,580,387
Endoscopy revenue	11,537,057	8,482,528	5,907,249	4,679,153
Cardiac tests revenue	10,292,715	7,372,213	5,776,422	3,735,590
Dentistry revenue	8,165,385	4,674,813	3,871,256	2,695,209
Other departments revenues	7,031,842	6,066,303	3,878,501	2,068,989
	<u>1,241,680,335</u>	<u>1,276,752,529</u>	<u>604,774,950</u>	<u>643,589,357</u>

All types of revenue are recognized at the revenue recognition point in time.

18. Operating costs

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Medical and pharmaceutical supplies	239,131,405	255,116,862	118,049,143	127,040,475
Salaries, wages and benefits	224,556,835	214,351,616	112,161,872	112,003,098
Doctors' fees	207,363,378	191,398,247	102,711,953	96,252,886
Fixed assets depreciation	48,806,444	44,825,436	24,937,314	22,620,314
Maintenance, spare parts and energy expenses	38,562,505	31,938,025	19,861,699	15,664,024
consumables costs	22,345,736	22,298,161	10,887,921	11,326,636
Lease amortization	9,869,838	8,588,653	4,834,373	4,060,144
Other expenses	36,952,208	27,547,219	19,189,733	15,130,871
	<u>827,588,349</u>	<u>796,064,219</u>	<u>412,634,008</u>	<u>404,098,448</u>

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

19. General and administrative expenses

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Salaries, wages, and benefits	95,076,499	82,158,495	47,089,153	40,693,402
Professional and consulting fees	14,283,630	12,773,931	8,390,629	5,802,618
Fixed assets depreciation	14,573,036	9,683,563	6,896,061	4,882,643
Intangible amortization	7,944,642	7,944,643	3,972,321	3,972,322
Service from others	11,424,352	6,586,995	6,775,818	2,125,890
Maintenance, spare parts and energy expenses	10,209,032	6,473,138	5,534,796	3,565,240
Lease amortization	3,196,283	4,200,443	1,628,193	2,536,276
Donations	279,600	1,226,600	139,800	(27,200)
consumables costs	1,222,456	1,081,351	630,163	517,729
Rent	486,980	706,777	198,588	252,688
Other expenses	25,024,527	28,026,535	10,439,800	14,845,629
	183,721,037	160,898,471	91,695,322	79,167,237

• The present value of the fair value of the part of the equity instruments of the acquisition of Bidaya Hospital (which represents 40% of the shares of the New Bedaya Company for Medical Centers and Hospitals) was estimated in June 2023 in exchange for 38,005,000 Egyptian pounds, of which 6,910,000 Egyptian pounds were recognized as part of the year's expenses, which represents the period from January 1, 2021 to June 30, 2022.

20. Impairment of financial assets

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Impairment in trade receivables	17,881,273	41,107,025	7,625,837	29,256,292
Impairment in cash at banks	77,828	(2,137,753)	287,225	(812,895)
	17,959,101	38,969,272	7,913,062	28,443,397

21. Earnings per share (basic / diluted)

The basic earnings per share is calculated by dividing the net profit for the period by the number of shares outstanding during the period.

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Distributable profit	164,426,846	191,883,619	74,052,209	90,574,706
Number of shares issued	1,600,000,000	1,600,000,000	1,600,000,000	1,600,000,000
The weighted average number of shares purchased (Treasury Shares)	(58,495,730)	(10,046,667)	(58,495,730)	(10,046,667)
The number of shares available after the purchase	1,541,504,270	1,589,953,333	1,541,504,270	1,589,953,333
Earnings per share	0,11	0,12	0,04	0,06

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Notes to the interim condensed consolidated financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

22. Commitments

Capital commitments:

Capital commitments at financial period end, which are not yet due, amounted to EGP 411,730,992 (31 December 2021: EGP 141,285,345).

23. Treasury shares

On February 24, 2022, the board of directors unanimously agreed that the company would purchase treasury shares from the stock market, and the purchase would be on the price of the security during the trading sessions. It was also unanimously agreed that the financing of the purchase process would be self-financing from the company's resources, and that purchase would take place from the session on February 27, 2022, until the implementation of the purchase of treasury shares amounting to a maximum of 10% of the company's total shares, without the participation of any of the main shareholders or Internal and their associated groups in accordance with the law.

Based on the decision of the Board of Directors, the group purchased 127,447,584 shares of its shares from the stock market for a total amount of 645,888,947 Egyptian pounds, and it was offered by deduction from the equity of treasury shares.

24. Significant and subsequent events

On 13 February 2020, the Cleopatra Hospital Company, the General Authority for River Transport, the Nile Badrawi Hospital Company and the heirs of Eng. Hassan Badrawi signed a comprehensive and final settlement agreement, according to which it was agreed to resolve, settle and end all disputes and claims related to the land on which Nile Badrawi Hospital was built. The total settlement amounted to EGP 36 million, bearing in mind that part of the settlement falls within the limits of the amounts deducted from the sale price of the shares of Nile Badrawi Hospital in favor of Cleopatra Hospital, and it was agreed to waive between the General Authority for River Transport and the Nile Badrawi Hospital Company for the disputes raised by each of them. Regarding the land being settled. On 30 June 31, 2021, the Administrative Court issued a ruling accepting the case in form and rejecting it in substance. The Cairo Governorate and the Nile Badrawi Hospital Company appealed the aforementioned ruling before the Supreme Administrative Court, and a court hearing was set for 21 June 2022, until both parties submit the settled settlement contracts between the parties.